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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common
ovulatory disorder in women of reproductive age,
with a reported prevalence of 6-10% (1, 2). PCOS is
a syndrome of ovarian dysfunction, and its cardinal
features are hyperandrogenism and polycystic ova-
ry morphology. Other common features are insu-
lin resistance, obesity, and elevated level of serum
luteinizing hormone (LH).
The 2003 Rotterdam PCOS Consensus Workshop
Group, sponsored by the European Society of Human
Reproduction and Embryology (ESHRE)/American
Society for Reproductive Medicine (ASRM), stipu-
lates that, in order to fit the definition of PCOS, two
or three out of the following criteria must be met :
chronic anovulation ; clinical and/or biochemical evi-
dence of hyperandrogenism ; and polycystic ovaries
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(3). These criteria have been widely accepted. On
the other hand, clinical and biochemical hyperan-
drogenism is less prevalent in Japanese patients than
in the Western population, and elevated LH levels
are more common in Japanese patients with PCOS
(4-6). The previous PCOS criteria of the Japanese
Society of Obstetrics and Gynecology (JSOG, 1993)
stipulate the presence of all three of the following
factors : chronic anovulation ; high LH level ; and
presence of polycystic ovaries (PCO) (4). Hyper-
androgenemia was included only as a referential fac-
tor in these criteria because assessment of serum
androgen in women has been difficult ; however, the
revised PCOS criteria presented by JSOG in 2007
(Table 1) require the presence of hyperandrogene-
mia or elevated LH with normal serum follicle-stim-
ulating hormone (FSH) for a diagnosis of PCOS, as
well as menstrual dysfunction and polycystic ovary
morphology. Therefore, assessment of serum andro-
gen has become more important than ever.
Total testosterone (T), one of the various andro-
gens in the blood, is often measured in patients with
PCOS. The problem is that T assay systems demon-
strate inter-kit variability, especially in lower con-
centrations, and this is important for the diagnosis
of hyperandrogenemia in women (7, 8). Recently,
one of the major T assay systems, ECLusys TESTO
I (Old T assay) was revised to become ECLusys
TESTO II (New T assay) (Roche Diagnostics K.K.,
Tokyo, Japan). In order to reduce the nonspecific re-
action in the immune reaction, these reagents immo-
bilize the immune complex by adding streptavidin-
coated magnetic microparticles. The measurement
principle of the reagents adopts the electrochemi-
luminescence immune assay (ECLIA). The ECLIA
applies the principle that applying voltage to ruthe-
nium fluorescent antibody or to ruthenium in the
ruthenium fluorescent antibody can produce con-
secutive stable light emission of that reagent.
Furthermore, because the change of primary an-
tibody improved the specificity for T, New T assay
has lower cross-reactivity than Old T assay with
dehydroepiandrosterone-sulfate (DHEA-S) and sev-
eral other hormones (9).
In this study, we used both New and Old T assays
to measure the subjects of normal cyclic women and
PCOS patients and evaluated both the improvement
in the detection rate of high testosterone level in
PCOS and the benefit of the new assay combined
with LH in the diagnosis of PCOS.
MATERIALS AND METHODS
Subjects
Ninety-two normal cyclic women (Control group)
and Eighty-six patients with ovulatory dysfunc-
tion with PCOS (PCOS group) were enrolled in
this study (Table 2). The Control group consisted
of euthyroid women with normal serum levels of
prolactin and thyroid-stimulating hormone (TSH)
who had ultrasonically normal ovaries and regular
menstrual cycles (25-38 days in length) with evi-
dence of ovulation (mid-luteal phase with serum
progesterone level10 ng/ml).
The PCOS patients were diagnosed using the
Table 1 Diagnostic Criteria of Polycystic Ovary Syndrome by JSOG
1. Menstrual disorder
2. Polycystic ovary morphology
3. Hyperandrogenemia or elevated serum LH with normal serum FSH
1) Menstrual disorder means amenorrhea, oligomenorrhea or anovulatory cycle.
2) Polycystic ovary morphology means to have many small follicles by transvaginal ultrasonography, at least one ovary must have
10 follicles or more with their diameter 2-9 mm.
3) Endocrinological inspection should be done after confirming there is no follicle with its diameter 1 cm or more, having no ovulatory
drugs or female sex hormones. The lower detection rate of elevated serum LH should be noted within 10 days from withdrawal
bleeding or menstruation.
4) Hyperandrogenemia means elevated serum total testosterone, free testosterone or androstendione.
5) Elevated serum LH is defined as higher level than normal average + 1SD(LH7 mIU/ml in Spac-S measuring system), and serum
LH is higher than serum FSH(LH/FSH ratio1 in Spac-S measuring system).
Higher LH referring to FSH without LH elevation could be approved in obesity cases(BMI is 25 or more ).
Relationship of each measuring system with Spac-S should be considered in the decision.
6) Exclusion of Cushing syndrome, adrenal enzyme disorder and recovery phase of amenorrhea due to weight loss should be done.
JSOG ; Japan Society of Obstetric and Gynecology (10)
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PCOS diagnostic criteria of JSOG 2007, as described
above (Table 1) (10), and all of them also met the
criteria of Rotterdam criteria 2003 (3).
This study was approved by the institutional Eth-
ics Committee of the University of Tokushima
School of Medicine, and was conducted in accor-
dance with the ethical standards of the Committee.
Written informed consent was obtained from all pa-
tients.
Blood sampling
Serum samples were collected in the mid-follicular
phase (day 7 to 9 of the menstrual cycle) in the Con-
trol group. Sampling was not timed to the menstrual
cycle in the PCOS group because all patients were
oligomenorrheic or amenorrheic ; however, sam-
pling was performed if no follicle more than 10 mm
in diameter was seen on transvaginal ultrasonogra-
phy on the scheduled day of blood sampling.
Hormone assays
All samples were assayed for T levels using Old
and New T assays. To reduce the nonspecific reac-
tion in the immune reaction, these reagents immo-
bilize the immune complex by adding streptavidin-
coated magnetic microparticles. An electrochemilu-
minescence immunoassay (ECLIA) reagent kit was
used for reference detection of T levels. ECLIA is
carried out based on the concept that voltage applied
to ruthenium fluorescent antibody or ruthenium in
the ruthenium fluorescent antibody can produce
consecutive stable light emission to that reagent.
New T assay, the revised ECLIA reagent for T,
has lower cross-reactivity than Old T assay with
DHEA-S and other several hormones. The change
of primary antibody has improved the specificity for
the T assay.
The normal range of serum T was defined as the
mean value1.96 SD of the serum T level in nor-
mal cyclic women. Therefore, the proportion of
women whose serum level of T exceeds normal
upper limit would be 2.5%.
Serum LH levels were measured by the immuno-
radiometric assay (IRMA) using the SPAC-S LH
kit (TFB, Inc., Tokyo, Japan) in 80 patients of the
PCOS group whose extra serum was adequate for
the LH assay.
Outcome measures
The following outcome measures were studied :
1) serum T levels of the two groups using Old and
New T assays ; 2) distribution of serum T levels
of the two groups using Old and New T assays ;
3) relative numbers of patients with elevated serum
T levels in the PCOS group using Old or New T
assay ; 4) correlation between serum T levels by
New T assay and body mass index (BMI) in the
PCOS group ; and 5) correlation between serum T
levels by New T assay and serum LH levels in the
PCOS group.
Statistical analysis
Data are expressed as the meanSD. Analysis of
differences in mean values were determined using
the t -test. Correlations between variables were de-
termined using Spearman’s rank order analysis. The
Chi-square test was used for elevated T distribution
between the groups or between the two assays. P
values0.01 were considered statistically significant.
The statistical software program JMP, version 6.0.0
(SAS Institute Japan Ltd., Tokyo, Japan) was used
for analysis.
RESULTS
Serum T levels by Old T assay were 0.340.14
ng/ml (meanSD) and 0.570.29 ng/ml in the
Control and the PCOS groups, respectively (Fig. 1).
Serum T levels by New T assay were 0.250.10
ng/ml and 0.460.20 ng/ml in the Control and the
PCOS groups, respectively. Serum T levels were
significantly higher in the PCOS group than in the
Control group, in both Old and New T assays (p
0.0001).
The distribution of serum T levels in the two
groups overlapped ; however, the serum T levels of
the PCOS group were distributed in a higher range
(Fig. 2). This distribution pattern seemed more ap-
parent in New T assay than in Old T assay.
The number of PCOS patients whose serum T lev-
els exceeded the upper limit of normal range was sig-
nificantly greater in New T assay (38/86, 44.2%) than
in Old T assay (26/86, 30.2%) (p0.05) (Table 3).
Table 2 Age and BMI of the study groups
Control PCOS
n 92 86
Age 33.04.5 29.35.5*
BMI 21.33.0 25.27.5**
* : p0.05 v.s. Control
** : p0.01 v.s. Control
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The number of patients whose serum T levels ex-
ceeded the upper limit of normal range were, of
course, greater in the PCOS group than in the Con-
trol group, in both Old and New T assays (p0.05).
Fig. 3 shows the distribution of serum T levels
between Old and New T assays in the Control and
PCOS groups. New T assay revealed elevated T in
38 PCOS patients ; Old T assay revealed elevated T
in only 26 PCOS patients. Twelve PCOS patients
were proved to have elevated T only by New T as-
say.
Serum T level in PCOS patients by New T assay
showed significant correlation with BMI (Fig. 4). On
the other hand, serum T level in PCOS patients by
New T assay showed no correlation with serum LH
level (Fig. 5). Furthermore, combined measurement
of both T and LH showed a higher detection rate of
hormonal abnormality in the PCOS group (54/80),
compared with single measurement of T (37/80) or
LH (36/80).
Fig. 3 Distribution of serum testosterone levels between Old
and New T assays in the Control group (, n=92) and PCOS
group (, n=86). Dashed lines mean the upper limits of the nor-
mal range in normal cyclic women : 0.70 ng/ml in Old T assay
and 0.47 ng/ml in New T assay.
Fig. 2 Distribution of serum testosterone levels in the Control
group ( , n=92) and PCOS group ( , n=86) in the two assays.
Upper limits of the normal range in normal cyclic women are
0.70 ng/ml in Old T assay and 0.47 ng/ml in New T assay.
Fig. 1 Serum testosterone level was significantly higher in the
PCOS group than in the Control group, by both Old T assay (up-
per panel) and New T assay (lower panel). * : p0.0001 vs. Con-
trol. Horizontal bar=SD.
Table 3 Subjects with elevated serum testosterone(T) level
were dominant in the PCOS group and elevated T was more
evident in New T assay than in Old T assay
Old T assay
Control PCOS
Normal T
(0.70 ng/ml) 91 60
Elevated T
(0.70 ng/ml) 1 26
a
New T assay
Control PCOS
Normal T
(0.47 ng/ml) 91 48
Elevated T
(0.47 ng/ml) 1 38
a,b
note. Significant greater number by Chi-square test (a, b)
a : p0.05, v.s. the Control group in each assay.
b : p0.05, v.s. Old T assay of the PCOS group.
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DISCUSSION
Hyperandrogenemia is the typical feature of
PCOS, and is listed as one of the essential elements
for the diagnosis of PCOS, not only in Western
countries (3), but also in Japan (10). However, accu-
rate measurement of the serum T level, which is a
major indicator of androgen synthesis in the gonads,
has been difficult in women because their serum
level is much lower than that of men ; therefore, the
cross-reaction with other steroid hormones severely
interferes with the precise diagnosis of hyperandro-
genic diseases in women. As for serum free testos-
terone(FT), which should have an important role in
assessment of the hyperandrogenemia/hyperandro-
genism, the assay system has shown low accuracy
in women range as seen in T assay. Serum FT was
not so frequently measured in patients without hir-
sutism, and limited data showed lower ability of FT
to distinguish PCOS and other ovulatory disorders
although elevated FT is highly detected in these pa-
tients (10). Recently, ECLusys TESTO I (Old T as-
say), one of the major assay systems for T, has been
revised to become TESTO II (New T assay), mainly
by reducing the cross-reactivity with DHEA-S of the
first antibody.
The present study assessed the efficacy of this re-
vision in the diagnosis of PCOS. We prepared ade-
quate number of serum samples for the present
analysis of 86 PCOS patients who were previously
diagnosed with PCOS and 92 normal cyclic women
as a Control group in order to measure T levels us-
ing both Old and New T assays. We additionally
evaluated the combined hormonal assessment of T
and LH in the diagnosis of PCOS. As a result, both
Old and New T assays revealed higher T levels and
an extremely higher proportion of patients with ele-
vated T in the PCOS group than in the Control
group. Furthermore, the proportion of patients with
elevated T in the PCOS group was significantly
higher in New T assay than in Old T assay, demon-
strating the improvement in the diagnosis of PCOS
in this revision of the assay system clearly. Old T as-
say detected elevated T in 30.2% of PCOS patients ;
however, New T assay detected it in as many as
44.2% of the same patient population. No patients
showed elevated T only in Old T assay. Detecting
elevated T used to be difficult ; in a 2007 report (10),
only 14.3% of PCOS patients were reported to have
elevated T in a Japanese survey from sum of data
using various T assay systems. The present result of
44.2%, detectable as elevated T in PCOS patients, is
higher than ever reported using the previous assay
systems in Japan (11). This remarkable advance in
T assay encourages the precise diagnosis of PCOS
in Japanese patients.
As for the measured value of T, New T assay
shows an almost 40% decrease compared with the
Old T assay in female samples, although almost the
same value is noted in male samples (12). There-
fore, when we compare the measured value between
these assays with respect to patients with female
reproductive disorders, we must take note of this
major reduction in the values. In the present study,
New T assay showed lower values than Old T assay
in both Control and PCOS groups. The reason for
Fig. 4 Relationship between body mass index (BMI) and se-
rum testosterone level measured by New T assay. A correlation
was found between BMI and serum testosterone level.
Fig. 5 Relationship between serum LH and serum testosterone
level measured by New T assay. No correlation was found be-
tween serum LH level and serum testosterone level. Dashed lines
mean cut-off value for the diagnosis of PCOS : 7.0 IU/ml for LH,
which is mean + 1 SD in normal cyclic women and 0.47 ng/ml
for testosterone, which is mean + 1.96 SD in normal cyclic
women. Number of patients in the four areas divided by two
dashed lines is shown in parentheses.
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this reduction in measured T values is well ex-
plained by the low cross-reaction to DHEA-S in the
New T assay. Some reports have demonstrated T
levels relatively higher than indicated by clinical
symptoms (13, 14). In basic studies, cross-reaction
to DHEA-S was reported as0.003% in New T as-
say and 0.01% in Old T assay (15, 16). Cross-reac-
tion to DHEA-S in New T assay would therefore be
lower than 30% of that in Old T assay. In Old T as-
say, 1 μg/dl of DHEA-S would raise the T value by
0.0008155 ng/ml (9). The difference in the serum
DHEA-S level between the sexes was not so great,
although T levels were 10 times higher in males
than in females. When the DHEA-S serum level is
300 μg/dl in males and 200 μg/dl in females as
around each mode of the normal range, 0.245 ng/
ml in males and 0.163 ng/ml in females would be
measured as T due to cross-reaction. In considering
the serum T level, the calculated value of the cross-
reaction is small in the male T level, however, it is
seriously large in the female T level. Therefore, Old
T assay was largely influenced by serum DHEA-S
and New T assay largely reduced this influence, re-
sulting in a 40% reduction in the measured values
only in females. For the same reason, a histogram of
the serum T levels of the Control and PCOS groups
in New T assay was apparently less overlapped com-
pared with Old T assay or other assay systems (11) ;
therefore, an elevated T level by New T assay is
higher than T levels determined by previous assay
systems.
Androgen synthesis in the theca cells of the ova-
ries is enhanced by hyperinsulinemia from insulin
resistance in PCOS patients, and insulin resistance
is enhanced by obesity (5). Therefore, serum T lev-
els correlated positively with BMI. On the other
hand, we demonstrated that serum T level showed
no correlation with serum LH level. T and LH are
important endocrinological disorders of PCOS which
do not correlate with each other. Therefore, meas-
urement of both these two hormones would in-
crease the detection rate of hormonal abnormality
in PCOS patients.
Endocrinological assessment of LH or T in pa-
tients with PCOS does have some problems. Re-
garding evaluation of T levels, low sensitivity has
been a major problem ; however, this has been im-
proved by a revision of assay systems. On the other
hand, problems in LH assessment have included
frequent fluctuation of serum levels by pulsatile se-
cretion at about 60-min intervals in PCOS, which
causes a 2-mIU difference according to the timing of
blood sampling. Endogenous or exogenous estrogen
and progesterone also influence the LH level. As a
result, the reproducibility of the serum LH level is
low (10, 17). Therefore, detection of elevated LH is
sometimes difficult and, in fact, some patients (26/
80) in the present study did not show elevated T or
LH, even though they were diagnosed with PCOS
by at least one hormonal examination previously. In
the diagnostic criteria for PCOS in Japan (10), a re-
quired endocrinological factor is elevated androgen
or LH. T and LH are thought to be complementary
to each other. In that report (10), combined T or
other androgens and the LH assay raised the detec-
tion rate of endocrinological disorders. However, the
T assay provided little contribution to the combined
assay (10) because of the low potential of the T as-
say in those days. In the present study, New T assay
showed an extremely higher potential for the detec-
tion of elevated T more than ever, giving a real
chance for success in the combined measurement
of T and LH. In the present study, patients with ele-
vated LH without T were seen in the proportion of
21.3% (17/80), and patients with elevated T without
LH constituted 22.5% (18/80). Patients with both T
and LH elevation made up only 23.8% (19/80). The
combined measurement of T and LH could detect
endocrinological disorder in 67.5% (54/80) of the
PCOS patients. New T assay combined with the LH
assay seemed effective in the diagnosis of PCOS.
In conclusion, we demonstrated an improvement
in the detection rate of elevated T in PCOS using the
same patient population using both previous and re-
vised T assay systems simultaneously, and we addi-
tionally showed that the T measurement by revised
T assay combined with LH measurement markedly
improved the diagnostic process for PCOS.
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